Featured Research

from universities, journals, and other organizations

Genetic Variation To Predict Initial Response To Warfarin Identified

Date:
March 8, 2008
Source:
NIH/National Heart, Lung and Blood Institute
Summary:
Scientists have identified which variations of a specific gene determine a patient's initial response to treatment with the blood-thinning (anticoagulant) drug warfarin. Researchers found that the gene VKORC1 plays a major role in determining a patient's initial sensitivity to warfarin treatment -- when dosage amounts are most critical to prevent clotting problems in patients.

Scientists have identified which variations of a specific gene determine a patient's initial response to treatment with the blood-thinning (anticoagulant) drug warfarin. Researchers with the National Institutes of Health (NIH) Pharmacogenetics Research Network found that the gene VKORC1 plays a major role in determining a patient's initial sensitivity to warfarin treatment -- when dosage amounts are most critical to prevent clotting problems in patients.

Researchers assessed CYP2C9 genotypes (CYP2C9 *1, *2, and *3) and VKORC1 haplotypes (designated A and nonA) in 297 patients starting warfarin therapy. They compared the participants' clinical characteristics and response to therapy, determined by international normalized ratio (INR) and bleeding events. Their findings confirm earlier research that the two genes, VKORC1 and CYP2C9, help predict how well a patient responds to warfarin. The new results take scientists' understanding a step further and indicate that although both genes significantly influence response to the drug after the first two weeks of therapy, only variations of VKORC1 predict response within the first week of therapy.

The blood clotting variations in VKORC1 help explain why certain patients require a lower or higher dose of warfarin to get its full benefits. The findings could ultimately help doctors determine a patient's optimal warfarin dose more quickly and precisely through genetic screening for the VKORC1 gene and could result in better warfarin dosing, thereby increasing the safety and effectiveness of treatment.

After the discovery of the two genes that play a role in warfarin responsiveness, the Food and Drug Administration (FDA) approved labeling changes in August 2007 instructing physicians to use genetic testing when determining initial dosage estimates for their patients. However, until now, information on genetic interactions with initial response to therapy was limited.

An estimated 2 million people in the United States take the anticoagulant drug warfarin to prevent harmful clotting after a heart attack, stroke, or major surgery. Despite its wide use, physicians find the drug challenging to prescribe because individuals' responses vary widely, and too high of a dose can result in excessive bleeding while too low a dose could allow dangerous blood clots to form.

The study was conducted by researchers at Vanderbilt University and funded by the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of General Medical Sciences (NIGMS), both part of NIH.

The article, "Genetic Determinants of Initial Warfarin Response," is published in the March 6, 2008, issue of the New England Journal of Medicine. An accompanying editorial written by NHLBI Director Elizabeth G. Nabel, M.D., and NHLBI Deputy Director Susan B. Shurin, M.D., on the role of pharmacogenomics is also in the NEJM.


Story Source:

The above story is based on materials provided by NIH/National Heart, Lung and Blood Institute. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Heart, Lung and Blood Institute. "Genetic Variation To Predict Initial Response To Warfarin Identified." ScienceDaily. ScienceDaily, 8 March 2008. <www.sciencedaily.com/releases/2008/03/080306103847.htm>.
NIH/National Heart, Lung and Blood Institute. (2008, March 8). Genetic Variation To Predict Initial Response To Warfarin Identified. ScienceDaily. Retrieved April 19, 2014 from www.sciencedaily.com/releases/2008/03/080306103847.htm
NIH/National Heart, Lung and Blood Institute. "Genetic Variation To Predict Initial Response To Warfarin Identified." ScienceDaily. www.sciencedaily.com/releases/2008/03/080306103847.htm (accessed April 19, 2014).

Share This



More Health & Medicine News

Saturday, April 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Nine-Month-Old Baby Can't Open His Mouth

Nine-Month-Old Baby Can't Open His Mouth

Newsy (Apr. 19, 2014) Nine-month-old Wyatt Scott was born with a rare disorder called congenital trismus, which prevents him from opening his mouth. Video provided by Newsy
Powered by NewsLook.com
'Holy Grail' Of Weight Loss? New Find Could Be It

'Holy Grail' Of Weight Loss? New Find Could Be It

Newsy (Apr. 18, 2014) In a potential breakthrough for future obesity treatments, scientists have used MRI scans to pinpoint brown fat in a living adult for the first time. Video provided by Newsy
Powered by NewsLook.com
Little Progress Made In Fighting Food Poisoning, CDC Says

Little Progress Made In Fighting Food Poisoning, CDC Says

Newsy (Apr. 18, 2014) A new report shows rates of two foodborne infections increased in the U.S. in recent years, while salmonella actually dropped 9 percent. Video provided by Newsy
Powered by NewsLook.com
Scientists Create Stem Cells From Adult Skin Cells

Scientists Create Stem Cells From Adult Skin Cells

Newsy (Apr. 17, 2014) The breakthrough could mean a cure for some serious diseases and even the possibility of human cloning, but it's all still a way off. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins